Clinical trial and research platform uMed, which is used by over 130 GPs and 350 patients in the UK, has landed £9.8m in funding to grow its user base in North America.
The firm expects to have access to more than 10 million patients by growing its North American presence before the end of the year
London-based uMed was started by anaesthetist and NHS doctor Dr Matt Wilson. The company’s platform is used by healthcare services to automate the discovery of relevant patient cohorts and for patient communications during clinical trials and research.
Dr Elango Vijakumar, national research lead at Modality Partnership, said: “We’ve been working alongside uMed since 2019 to provide our patients with the opportunity to participate in multiple research programmes.”
Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital provided the capital for uMed’s funding round. It comes after a £3.7m seed round for the health tech company in 2020.
“We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research,” said Wilson, who is also the CEO of uMed.
It began with interstitial lung diseases in collaboration with the Three Lakes Foundation, and plans to increase its offering to cardio-metabolic and lung disease cohorts.
A competitor to uMed is Peter Thiel-backed clinical trial software developer Lindus Health, which scored £436,603 earlier this year.